Navigation Links
New therapy prevents dangerous side effect for lymphoma patients
Date:12/9/2008

SAN FRANCISCO - Patients respond well to a new three-drug combination for indolent B cell lymphoma that also spares them prolonged, potentially lethal, suppression of blood production in the bone marrow, researchers at The University of Texas M. D. Anderson Cancer Center report today at the 50th annual meeting of the American Society of Hematology.

Pentostatin, cyclophosphamide and rituximab together are providing the same remission rate as other combinations but with minimal long-term bone marrow suppression, said study presenter Felipe Samaniego, M.D., associate professor in M. D. Anderson's Department of Lymphoma and Melanoma.

Myelosuppression leads to production of fewer red blood cells, white blood cells and platelets. When prolonged, it can lead to myelodysplastic syndrome, which comprises several conditions that cause potentially lethal insufficient blood production.

"The worst outcome of long-term myelosuppression for indolent B cell lymphoma patients is myelodysplastic syndrome," Samaniego said. "In this study, out of 80 patients, none developed MDS."

And 77 of 80 (96 percent) experienced either complete remission or unconfirmed complete remission. Some did have low blood counts, but all were short-term. Overall, the combination is well-tolerated, the research team reported.

Prolonged myelosuppression also makes treatment much more difficult if a patient's lymphoma recurs, Samaniego said. "Patients treated with myelosuppressing agents have a difficult time tolerating another round of chemotherapy if their lymphoma comes back."

Indolent B cell lymphomas comprise follicular lymphoma, small lymphocytic lymphoma, and marginal zone lymphoma. These slow-growing but potentially lethal cancers are the most common form of non-Hodgkin lymphoma.

Samaniego and colleagues have been testing new drug combinations against indolent B cell lymphoma that reduce myelosuppression.

Two years ago, a combination of fludarabine, mitoxantrone and dexamethasone with rituximab and interferon alpha reduced the incidence of MDS to 4 percent of patients, down from a historical rate of around 10 percent.

The key ingredient in pushing the MDS rate to zero, Samaniego says, was substitution of fludarabine with pentostatin. Both are nucleoside analogs, which interfere with DNA reproduction, and target lymphoid cells, making them attractive drugs for lymphomas.

Earlier research indicated that pentostatin is less toxic to bone marrow than other members of this drug class.

"The PCR combination is a very promising therapy for indolent B cell lymphoma," Samaniego said.


'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Related medicine news :

1. Intense chemotherapy wards off recurrence in half of mantle cell lymphoma patients after seven years
2. Statin Use Doesnt Inhibit Lymphoma Drug Therapy
3. Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkins Lymphoma
4. 33rd Annual Hutch Holiday Gala Raises Millions for Cancer Immunotherapy Research
5. Lenalidomide safe as single therapy for elderly CLL patients
6. Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission
7. The St. John-Clark Pain Treatment Center Forms Manual Therapy 'Dream Team'
8. Aggressive Therapy May Stem CF Progression in Infants
9. Washington State Health Care Authority to Launch Medication Therapy Management Initiative
10. MaxCyte to Present Targeted Cancer Immunotherapy Product at 50th Annual Meeting of the American Society of Hematology
11. Oncologists Rank Aloxis Marketing Message Most Influential in the Chemotherapy-Induced Nausea and Vomiting Drug Market
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New therapy prevents dangerous side effect for lymphoma patients
(Date:2/19/2017)... ... February 19, 2017 , ... "At ... better care, and MEDfx and the Delaware Health Information Network (DHIN) have partnered ... the nation’s first state-wide health information exchange, DHIN stores and shares real-time health ...
(Date:2/18/2017)... ... February 17, 2017 , ... CONTACT:, Glenn ... Beverly Hills plastic surgeon Dr. Glenn Vallecillos experiments SculpSure, the hot, ... "Traditionally, plastic surgery has been centered around that idea that to achieve ones ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... not kept pace. Enovate Medical has introduced an innovative workstation designed to reduce ... supporting nurses, the Encore Mobile EHR Workstation offers a lightweight, highly mobile, multi-functional ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Dr. Carol Francis' goals for each and every seminar, session and class ... will demonstrate five different brainwave tools which help energize creativity, focus mental functions, ...
(Date:2/17/2017)... ... February 17, 2017 , ... MAP Revenue ... that Karen Pilley has been promoted to Chief Executive Officer. , The ... paradigm – a shift that demands the transition from pay-for-service to pay-for-performance models. ...
Breaking Medicine News(10 mins):
(Date:2/18/2017)... Research and Markets has announced the addition of the "Contraceptives ... ... for the US, Canada , Japan ... Latin America , and Rest of World. Annual estimates and ... historic analysis is provided for these markets. Market data and analytics are ...
(Date:2/17/2017)... Feb. 17, 2017  Ethicon, Inc. today announced ... a privately held medical device company that manufactures ... System, a novel minimally invasive device for the ... Medical will enable Ethicon to offer patients a ... Nissen fundoplication surgical procedure. 1 ...
(Date:2/17/2017)... DUBLIN , Feb. 17, 2017 ... ("Theravance Biopharma" or the "Company") today announced the ... novel, potent, and orally administered pan-Janus kinase (JAK) ... 12 th Congress of the European Crohn,s ... the Company reported further data from its completed ...
Breaking Medicine Technology: